Skip to main content

Head and Neck Cancer

New Saliva Test Accurately Detects HPV-Associated Head and Neck Cancer
By William King
Head and Neck Cancer
TOP - November 2021 Vol 14, No 7
Oropharyngeal cancer, which can develop at the base of the tongue, tonsils, and the middle part of the throat, is primarily caused by human papillomavirus (HPV) infection, the most common sexually transmitted virus and infection in the United States.1 Read More ›
November 4, 2019 — Oncology News & Updates
Financial Toxicity, Head and Neck Cancer, Hematologic Cancers, In the News, Leukemia
Web Exclusives
  • Xospata Extends Overall Survival in Patients with FLT3 Mutation–Positive Relapsed or Refractory Acute Myeloid Leukemia
  • Published Results from KEYNOTE-048 Trial Show Extended Survival with Keytruda in Advanced Head and Neck Cancers
  • Discussing Costs of Genomic Testing with Patients
Read More ›
Oral Cancer and Sex in the Era of HPV Infection
By Meg Barbor, MPH
Head and Neck Cancer
Web Exclusives
San Francisco, CA—The increasing rate of infection with the human papilloma­virus (HPV) in the United States has changed the field of head and neck cancer, or oral cancer, and HPV infection now causes a growing majority (70%-90%) of oropharyngeal squamous-cell carcinomas. As its incidence is rising, so is patients’ curiosity about what sets this cancer apart from other malignancies. Read More ›
Low Survival in Patients with Head and Neck Cancers Linked to Delays in Radiation Therapy After Surgery
Low Survival in Patients with Head and Neck Cancers Linked to Delays in Radiation Therapy After Surgery
By Corbin Davis
Head and Neck Cancer
TOP - August 2018, Vol 11, No 2

Current National Comprehensive Cancer Network guidelines recommend initiating radiation therapy within 6 weeks of tumor resection, but the benefits of shorter time to radiation therapy, including locoregional control and survival, remain inconclusive.

Read More ›
Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer
Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer
By Eric Allan, MD
Head and Neck Cancer, Audiocast
Audiocasts
Eric Allan, MD, discusses the clinical significance of his research and case study, “Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer.” Read More ›
Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419
Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419
By Carryn Anderson, MD
Head and Neck Cancer, Audiocast
Audiocasts
Carryn Anderson, MD, discusses the clinical significance of her research on, “Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419.” Read More ›
Low-Level Laser Therapy Reduces Pain in Patients with Head and Neck Cancer
By Meg Barbor, MPH
Head and Neck Cancer
TOP - May 2016, Vol 9, No 2
Scottsdale, AZ—Therapeutic, low-level laser therapy (LLLT) reduces pain and accelerates the resolution of oral mucositis (OM) in patients with head and neck cancer receiving chemoradiotherapy (CRT), according to Eric Allan, MD. Read More ›
Severe Oral Mucositis Less Frequent, Briefer, Less Severe with Use of GC4419
By Meg Barbor, MPH
Head and Neck Cancer
TOP - May 2016, Vol 9, No 2
Scottsdale, AZ—The superoxide dismutase mimetic GC4419 markedly reduced the incidence, intensity, and duration of severe oral mucositis in a study of patients with head and neck cancer. Read More ›
Prophylactic Gabapentin Linked to Weight Loss, Narcotic Dependency
By Meg Barbor, MPH
Conference Correspondent, Head and Neck Cancer
TOP - May 2016, Vol 9, No 2
Scottsdale, AZ—Patients with oropharyngeal cancer undergoing radiation therapy experienced diminished narcotic dependency and weight loss with the use of prophylactic gabapentin. Read More ›
Infrastructure Issues in the US Drug Supply: Where Did the Drugs Go?
By Timothy G. Tyler, PharmD, FCSHP
Head and Neck Cancer
Web Exclusives

North America is facing a shortage of certain drugs, and you do not have to be a pharmacist buyer tasked with procurement to realize our drug supply is under pressure. Governmental and professional groups—including the US Food and Drug Administration (FDA), American Society of Clinical Oncology (ASCO), Institute for Safe Medication Practices (ISMP), Association of Community Cancer Center, and American Pharmacists Associ ation, among others—have been stating that this is a serious problem that may not be resolved anytime soon. Read More ›

Page 1 of 2